Specifically, Vierasu et al. investigated BCR PCa patients (n = 54, median PSA 1.66 ng/mL) with 18F-JK-PSMA-7 dPET leveraging a reduced dose and acquisition time (20% and 50%, respectively) and demonstrating a comparable diagnostic performance [47]. The gene discussed is BCR; the disease is posterior cortical atrophy.